<code id='AE1EAC64C6'></code><style id='AE1EAC64C6'></style>
    • <acronym id='AE1EAC64C6'></acronym>
      <center id='AE1EAC64C6'><center id='AE1EAC64C6'><tfoot id='AE1EAC64C6'></tfoot></center><abbr id='AE1EAC64C6'><dir id='AE1EAC64C6'><tfoot id='AE1EAC64C6'></tfoot><noframes id='AE1EAC64C6'>

    • <optgroup id='AE1EAC64C6'><strike id='AE1EAC64C6'><sup id='AE1EAC64C6'></sup></strike><code id='AE1EAC64C6'></code></optgroup>
        1. <b id='AE1EAC64C6'><label id='AE1EAC64C6'><select id='AE1EAC64C6'><dt id='AE1EAC64C6'><span id='AE1EAC64C6'></span></dt></select></label></b><u id='AE1EAC64C6'></u>
          <i id='AE1EAC64C6'><strike id='AE1EAC64C6'><tt id='AE1EAC64C6'><pre id='AE1EAC64C6'></pre></tt></strike></i>

          hotspot

          hotspot

          author:fashion    Page View:53437
          BiTE Bridge
          Illustration of a BiTE, Amgen's bispecific antibodies Amgen

          In cancer immunotherapy these days, technology is advancing so fast that 2017’s buzzy new treatment may soon be passe: Only 18 months after approval of the first CAR-T, pharmaceutical companies and biotechs are already talking about next-generation cancer therapy.

          Called bispecific antibodies, they’re being developed by some two dozen companies large and small, with a version cleverly branded as BiTEs already constituting 60 percent of Amgen’s oncology pipeline. The appeal: Bispecifics make the immune system kill tumor cells like first-gen immunotherapy, but, unlike the weeks it takes to laboriously manufacture CAR-Ts, they can start being infused almost as quickly as an oncologist can write a prescription.

          advertisement

          “We’re very bullish” on BiTEs, said Dr. David Reese, head of R&D at Amgen, which has the only cancer-targeting bispecific approved for clinical use in the U.S. and 14 more in development, including for multiple myeloma, small cell lung cancer, glioblastoma, and other solid tumors. “We can generate a BiTE against any tumor antigen we want to go after.”

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          Stem cell clinics for heart failure: buyer be wary
          Stem cell clinics for heart failure: buyer be wary

          Embryonicstemcellsasseenthroughamicroscope.MauricioLima/AFP/GettyImagesWearewitnessinggreatpromisein

          read more
          New air purifier tech could be key to improving indoor air quality
          New air purifier tech could be key to improving indoor air quality

          AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

          read more

          AI can’t replace a physician’s gut feeling

          AdobeI’veheard“WebMDsaiditcouldbecancer”countlesstimesinmy15yearsworkingasanemergencymedicinephysici